Gene · 2230
Papers1,417
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,417
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cuproptosis enters the cancer-immunity circuit. | Cell | 2026 | 42624074 | PubTator, text mining | PubMed |
| Unraveling the Crosstalk Between Ferroptosis and Cuproptosis for Rational Nanomedicine Design in Cancer. | Int J Nanomedicine | 2026 | 42622024 | PubTator, text mining | PubMed |
| FGFR4 suppresses antitumor immunity and cuproptosis by disrupting CYLD-mediated stabilization of STING and FDX1. | Cancer Lett | 2026 | 42617725 | PubTator, text mining | PubMed |
| A Degradable Nanoplatform Integrating Glucose Oxidase and Copper Selenide for Near-Infrared-Enhanced Multimodal Synergistic Therapy in Lung Cancer. | Biomater Res | 2026 | 42602275 | PubTator, text mining | PubMed |
| Metabolic cell death networks in Alzheimer's disease: mechanistic links and therapeutic perspectives of ferroptosis, cuproptosis, and disulfidptosis. | Front Cell Dev Biol | 2026 | 42597683 | PubTator, text mining | PubMed |
| METTL14 knockdown alleviates inflammation in oral lichen planus by driving macrophage M2 polarization through mediating FDX1 m6A modification. | Cytotechnology | 2026 | 42597579 | PubTator, text mining | PubMed |
| GSH-responsive self-assembled nanoplatform synergistically enhances cuproptosis through metabolic reprogramming and oxidative stress amplification. | Mater Today Bio | 2026 | 42571356 | PubTator, text mining | PubMed |
| Engineering cuproptosis with nanomedicine: Design, combination therapy, and translation in cancer. | Mater Today Bio | 2026 | 42569284 | PubTator, text mining | PubMed |
| C1R suppresses hepatocellular carcinoma cell aggressiveness through promoting HIF-1α degradation and modulating cuproptosis-related protein expression. | Int Immunopharmacol | 2026 | 42561667 | PubTator, text mining | PubMed |
| Copper homeostasis and cuproptosis: New perspectives on the diagnosis and treatment of metabolic diseases. | J Trace Elem Med Biol | 2026 | 42551357 | PubTator, text mining | PubMed |
| Engineering ZCIF@GSK Nanoplatform to Overcome Tumor Metabolism: LDHA Inhibition-Mediated Cuproptosis for Highly Efficient Oncotherapy. | Adv Healthc Mater | 2026 | 42544722 | PubTator, text mining | PubMed |
| Dihydrolipoamide dehydrogenase promotes hepatocellular carcinoma progression and modulates cuproptosis-dependent cell death. | Funct Integr Genomics | 2026 | 42525162 | PubTator, text mining | PubMed |
| Arecoline promotes oral submucous fibrosis by enhancing epithelial cell cuproptosis through PUS1-mediated pseudouridylation. | 3 Biotech | 2026 | 42523757 | PubTator, text mining | PubMed |
| Silencing SLC31A1 attenuates high glucose plus copper-induced cuproptosis-like signaling, oxidative stress, and barrier dysfunction in human retinal microvascular endothelial cells. | Int J Ophthalmol | 2026 | 42523602 | PubTator, text mining | PubMed |
| From ROS to Cuproptosis: The molecular evolution of copper nanotherapeutics. | Biochem Biophys Res Commun | 2026 | 42492190 | PubTator, text mining | PubMed |
| UHRF1 inhibits cuproptosis in lung adenocarcinoma via promoting FDX1 promoter methylation. | Respir Res | 2026 | 42477749 | PubTator, text mining | PubMed |
| Copper homeostasis and cuproptosis rewire the tumor microenvironment: mechanisms, immune modulation, and therapeutic opportunities. | J Hematol Oncol | 2026 | 42471718 | PubTator, text mining | PubMed |
| Cuproptosis: A Potential Target for the Treatment of Systemic Lupus Erythematosus. | J Inflamm Res | 2026 | 42445351 | PubTator, text mining | PubMed |
| From copper imbalance to immunometabolic remodeling: cuproptosis-related vulnerability and therapeutic hypotheses in autoimmune diseases. | Inflamm Res | 2026 | 42435071 | PubTator, text mining | PubMed |
| Multi-compartment immune and tumor cell reprogramming by IFNa2 overcomes colon cancer immunotherapy resistance. | bioRxiv | 2026 | 42427502 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2230/papers?page=2